Artivion, Inc. (NYSE:AORT) Short Interest Up 16.6% in April

02 May 2026, 16:03 by Jessica Moore · The Cerbat Gem

Artivion, Inc. (NYSE:AORT – Get Free Report) saw a large growth in short interest in April. As of April 15th, there was short interest totaling 1,943,835 shares, a growth of 16.6% from the March 31st total of 1,667,100 shares. Based on an average daily volume of 523,130 shares, the short-interest ratio is currently 3.7 days. Approximately 4.3% of the company’s stock are short sold.

Wall Street Analyst Weigh In

AORT has been the topic of a number of research analyst reports. LADENBURG THALM/SH SH raised Artivion from a “neutral” rating to a “buy” rating and set a $42.00 target price on the stock in a report on Friday, April 10th. Canaccord Genuity Group lowered their target price on Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Weiss Ratings raised Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, Needham & Company LLC reaffirmed a “buy” rating on shares of Artivion in a report on Monday, April 20th. Seven analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.00.

Check Out Our Latest Research Report on AORT

Artivion Price Performance

Shares of Artivion stock traded up $0.44 during midday trading on Friday, hitting $36.27. 288,439 shares of the company were exchanged, compared to its average volume of 365,148. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62. The firm has a market cap of $1.76 billion, a P/E ratio of 181.33 and a beta of 1.41. Artivion has a 52 week low of $23.15 and a 52 week high of $48.25. The firm has a 50 day simple moving average of $36.60 and a 200-day simple moving average of $41.32.

Artivion (NYSE:AORT – Get Free Report) last posted its earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The business had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. The business’s revenue for the quarter was up 19.2% compared to the same quarter last year. Research analysts forecast that Artivion will post 0.63 earnings per share for the current year.

Insider Buying and Selling

In other news, SVP Jean F. Holloway sold 8,962 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $38.00, for a total transaction of $340,556.00. Following the transaction, the senior vice president owned 185,095 shares of the company’s stock, valued at approximately $7,033,610. This represents a 4.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Lance A. Berry sold 6,316 shares of the stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $238,618.48. Following the transaction, the executive vice president directly owned 210,827 shares in the company, valued at approximately $7,965,044.06. This represents a 2.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 133,043 shares of company stock worth $4,977,158. Insiders own 6.30% of the company’s stock.

Hedge Funds Weigh In On Artivion

Several institutional investors have recently bought and sold shares of AORT. Aster Capital Management DIFC Ltd raised its position in Artivion by 402.3% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after purchasing an additional 519 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Artivion in the third quarter valued at about $27,000. Rockefeller Capital Management L.P. increased its position in Artivion by 150.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after purchasing an additional 399 shares during the period. Larson Financial Group LLC raised its holdings in Artivion by 148.5% during the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after purchasing an additional 563 shares during the last quarter. Finally, USA Financial Formulas boosted its stake in shares of Artivion by 163.5% in the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after purchasing an additional 703 shares during the last quarter. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

(Get Free Report)

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.